{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T07:31:21Z","timestamp":1793431881436,"version":"4.5.0"},"reference-count":85,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,3,22]],"date-time":"2022-03-22T00:00:00Z","timestamp":1647907200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Therapeutic drug monitoring (TDM) of tyrosine kinase inhibitors (TKIs) is not yet performed routinely in the standard care of oncology patients, although it offers a high potential to improve treatment outcome and minimize toxicity. TKIs are perfect candidates for TDM as they show a relatively small therapeutic window, a wide inter-patient variability in pharmacokinetics and a correlation between drug concentration and effect. Moreover, most of the available TKIs are susceptible to various drug-drug interactions and medication adherence can be checked by performing TDM. Plasma, obtained<jats:italic>via<\/jats:italic>traditional venous blood sampling, is the standard matrix for TDM of TKIs. However, the use of plasma poses some challenges related to sampling and stability. The use of dried blood microsamples can overcome these limitations. Collection of samples<jats:italic>via<\/jats:italic>finger-prick is minimally invasive and considered convenient and simple, enabling sampling by the patients themselves in their home-setting. The collection of small sample volumes is especially relevant for use in pediatric populations or in pharmacokinetic studies. Additionally, working with dried matrices improves compound stability, resulting in convenient and cost-effective transport and storage of the samples. In this review we focus on the different dried blood microsample-based methods that were used for the quantification of TKIs. Despite the many advantages associated with dried blood microsampling, quantitative analyses are also associated with some specific difficulties. Different methodological aspects of microsampling-based methods are discussed and applied to TDM of TKIs. We focus on sample preparation, analytics, internal standards, dilution of samples, external quality controls, dried blood spot specific validation parameters, stability and blood-to-plasma conversion methods. The various impacts of deviating hematocrit values on quantitative results are discussed in a separate section as this is a key issue and undoubtedly the most widely discussed issue in the analysis of dried blood microsamples. Lastly, the applicability and feasibility of performing TDM using microsamples in a real-life home-sampling context is discussed.<\/jats:p>","DOI":"10.3389\/fonc.2022.821807","type":"journal-article","created":{"date-parts":[[2022,3,28]],"date-time":"2022-03-28T16:06:58Z","timestamp":1648483618000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":34,"title":["Therapeutic Drug Monitoring of Tyrosine Kinase Inhibitors Using Dried Blood Microsamples"],"prefix":"10.3389","volume":"12","author":[{"given":"Nick","family":"Verougstraete","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronique","family":"Stove","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain G.","family":"Verstraete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe P.","family":"Stove","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,3,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14372","article-title":"Barriers and Opportunities for the Clinical Implementation of Therapeutic Drug Monitoring in Oncology","volume":"87","author":"Menz","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.43.5362","article-title":"Evidence for Therapeutic Drug Monitoring of Targeted Anticancer Therapies","volume":"30","author":"Gao","year":"2012","journal-title":"J Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.105.084145","article-title":"Role of Tyrosine Kinase Inhibitors in Cancer Therapy","volume":"315","author":"Arora","year":"2005","journal-title":"J Pharamcol Exp Ther"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-019-02704-2","article-title":"Individualized Dosing of Oral Targeted Therapies in Oncology is Crucial in the Era of Precision Medicine","volume":"75","author":"Groenland","year":"2019","journal-title":"Eur J Clin Pharmacol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-020-03014-8","article-title":"Therapeutic Drug Monitoring of Oral Targeted Antineoplastic Drugs","volume":"77","author":"Mueller-Schoell","year":"2021","journal-title":"Eur J Clin Pharmacol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1097\/FTD.0000000000000699","article-title":"Therapeutic Drug Monitoring of Targeted Anticancer Protein Kinase Inhibitors in Routine Clinical Use: A Critical Review","volume":"42","author":"Cardoso","year":"2020","journal-title":"Ther Drug Monit"},{"key":"B7","doi-asserted-by":"publisher","first-page":"551","DOI":"10.2165\/11593320-000000000-00000","article-title":"Clinical Pharmacokinetics of Tyrosine Kinase Inhibitors: Focus on Pyrimidines, Pyridines and Pyrroles","volume":"50","author":"Di Gion","year":"2011","journal-title":"Clin Pharmacokinet"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2015.03.005","article-title":"Variability in Bioavailability of Small Molecular Tyrosine Kinase Inhibitors","volume":"41","author":"Herbrink","year":"2015","journal-title":"Cancer Treat Rev"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-020-04107-1","article-title":"Antifungal Prophylaxis and Novel Drugs in Acute Myeloid Leukemia: The Midostaurin and Posaconazole Dilemma","volume":"99","author":"Stemler","year":"2020","journal-title":"Ann Hematol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-020-00888-w","article-title":"Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor","volume":"59","author":"James","year":"2020","journal-title":"Clin Pharmacokinet"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-2235","article-title":"Effects of Smoking on the Pharmacokinetics of Erlotinib","volume":"27","author":"Hamilton","year":"2006","journal-title":"Clin Cancer Res"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/bcpt.12801","article-title":"Role of Cytochrome P450 3A4 and 1A2 Phenotyping in Patients With Advanced Non-Small-Cell Lung Cancer Receiving Erlotinib Treatment","volume":"121","author":"Parra-Guillen","year":"2017","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40262-017-0571-z","article-title":"Effect of Adherence on Pharmacokinetic\/ Pharmacodynamic Relationships of Oral Targeted Anticancer Drugs","volume":"57","author":"Cardoso","year":"2018","journal-title":"Clin Pharmacokinet"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0000000000000771","article-title":"Evaluation of Imatinib Concentrations in Samples Submitted for BCR-ABL1 or Imatinib Testing \u2013 Evidence to Support Therapeutic Drug Monitoring for Dose Optimization","volume":"42","author":"Smy","year":"2020","journal-title":"Ther Drug Monit"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/94.9.652","article-title":"Adherence to Therapy With Oral Antineoplastic Agents","volume":"94","author":"Partridge","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.3087","article-title":"Adherence Is the Critical Factor for Achieving Molecular Responses in Patients With Chronic Myeloid Leukemia Who Achieve Complete Cytogenetic Responses on Imatinib","volume":"28","author":"Marin","year":"2010","journal-title":"J Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2014.04.015","article-title":"Review of Therapeutic Drug Monitoring of Anticancer Drugs Part Two \u2013 Targeted Therapies","volume":"50","author":"Widmer","year":"2014","journal-title":"Eur J Cancer"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2016.4780","article-title":"Therapeutic Drug Monitoring and Tyrosine Kinase Inhibitors","volume":"12","author":"Herviou","year":"2016","journal-title":"Oncol Lett"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.787","article-title":"Practical Recommendations for Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology","volume":"102","author":"Verheijen","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2021.08.033","article-title":"Therapeutic Drug Monitoring in Oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology Consensus Guidelines for Imatinib Therapy","volume":"157","author":"Clarke","year":"2021","journal-title":"Eur J Cancer"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2020.113102","article-title":"Opportunities and Obstacles for Microsampling Techniques in Bioanalysis: Special Focus on DBS and VAMS","volume":"182","author":"Londhe","year":"2020","journal-title":"J Pharm BioMed Anal"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2015.10.033","article-title":"Liquid Chromatography \u2013 Tandem Mass Spectrometric Assay for the Simultaneous Determination of the Irreversible BTK Inhibitor Ibrutinib and its Dihydrodiol-Metabolite in Plasma and its Application in Mouse Pharmacokinetic Studies","volume":"118","author":"Rood","year":"2016","journal-title":"J Pharm BioMed Anal"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.talanta.2021.122140","article-title":"Quantification of Eight Hematological Tyrosine Kinase Inhibitors in Both Plasma and Whole Blood by a Validated LC-MS\/MS Method","volume":"226","author":"Verougstraete","year":"2021","journal-title":"Talanta"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2011.02.023","article-title":"Simultaneous Determination of Nine Tyrosine Kinase Inhibitors by 96-Well Solid-Phase Extraction and Ultra Performance LC-MS\/MS","volume":"412","author":"Bouchet","year":"2011","journal-title":"Clin Chim Acta"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2009.04.045","article-title":"Therapeutic Drug Monitoring of the New Targeted Anticancer Agents Imatinib, Nilotinib, Dasatinib, Sunitinib, Sorafenib and Lapatinib by LC Tandem Mass Spectrometry","volume":"877","author":"Haouala","year":"2009","journal-title":"J Chromatogr B Analyt Technol BioMed Life Sci"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.728","article-title":"The Use of Dried Blood Spots for Pharmacokinetic Monitoring of Vemurafenib Treatment in Melanoma Patients","volume":"56","author":"Nijenhuis","year":"2016","journal-title":"J Clin Pharmacol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s00216-012-6440-6","article-title":"Evaluation of Dried Blood Spot (DBS) Technology Versus Plasma Analysis for the Determination of MK-1775 by HILIC-MS\/MS in Support of Clinical Studies","volume":"404","author":"Xu","year":"2012","journal-title":"Anal Bioanal Chem"},{"key":"B28","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s00228-015-1961-5","article-title":"Characterization of the Disposition of Fostamatinib in Japanese Subjects Including Pharmacokinetic Assessment in Dry Blood Spots: Results From Two Phase I Clinical Studies","volume":"72","author":"Martin","year":"2016","journal-title":"Eur J Clin Pharmacol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0b013e31819e91ce","article-title":"Dried Blood Spot Methods in Therapeutic Drug Monitoring: Methods, Assays, and Pitfalls","volume":"31","author":"Edelbroek","year":"2009","journal-title":"Ther Drug Monit"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-014-0177-7","article-title":"Therapeutic Drug Monitoring by Dried Blood Spot: Progress to Date and Future Directions","volume":"53","author":"Wilhelm","year":"2014","journal-title":"Clin Pharmacokinet"},{"key":"B31","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.trac.2016.01.030","article-title":"Opening the Toolbox of Alternative Sampling Strategies in Clinical Routine: A Key-Role for (LC-)MS\/MS","volume":"84","author":"Velghe","year":"2016","journal-title":"TrAC"},{"key":"B32","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/B978-0-12-802025-8.00013-1","article-title":"\u201cAlternative Sampling Strategies for Therapeutic Drug Monitoring\u201d","volume-title":"Clinical Challenges in Therapeutic Drug Monitoring","author":"Capiau","year":"2016"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.chroma.2020.461731","article-title":"A Review of Recent Advances in Microsampling Techniques of Biological Fluids for Therapeutic Drug Monitoring","volume":"1635","author":"Tey","year":"2021","journal-title":"J Chromatogr A"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1002\/bmc.4445","article-title":"Review of DBS Methods as a Quantitative Tool for Anticancer Drugs","volume":"33","author":"Sulochana","year":"2019","journal-title":"BioMed Chromatogr"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2021.114418","article-title":"Volumetric Absorptive Microsampling as a Suitable Tool to Monitor Tyrosine Kinase Inhibitors","volume":"207","author":"Verougstraete","year":"2021","journal-title":"J Pharm BioMed Anal"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.4155\/bio.15.101","article-title":"DBS Sampling in Imatinib Therapeutic Drug Monitoring: From Method Development to Clinical Application","volume":"7","author":"Antunes","year":"2015","journal-title":"Bioanalysis"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1111\/jphp.12757","article-title":"Dried Blood Spot Sampling of Nilotinib in Patients With Chronic Myeloid Leukaemia: A Comparison With Venous Blood Sampling","volume":"69","author":"Boons","year":"2017","journal-title":"J Pharm Pharmacol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.558","article-title":"Dried Blood Spot Analysis for Therapeutic Drug Monitoring of Pazopanib","volume":"55","author":"de Wit","year":"2015","journal-title":"J Clin Pharmacol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0225225","article-title":"Development and Validation of LC-MS\/MS Method for Imatinib and Norimatinib Monitoring by Finger-Prick DBS in Gastrointestinal Stromal Tumor Patients","volume":"14","author":"Iacuzzi","year":"2019","journal-title":"PloS One"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2018.04.027","article-title":"Development and Validation of a Method for Gefitinib Quantification in Dried Blood Spots Using Liquid Chromatography-Tandem Mass Spectrometry: Application to Finger-Prick Clinical Blood Samples of Patients With Non-Small Cell Lung Cancer","author":"Irie","year":"2018","journal-title":"J Chromatogr B Analyt Technol BioMed Life Sci"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2012.07.011","article-title":"Simultaneous Measurement of Imatinib, Nilotinib and Dasatinib in Dried Blood Spot by Ultra High Performance Liquid Chromatography Tandem Mass Spectrometry","volume":"903","author":"Kralj","year":"2012","journal-title":"J Chromatogr B Analyt Technol BioMed Life Sci"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.13124","article-title":"Development of a Dried Blood Spot Sampling Method Towards Therapeutic Monitoring of Radotinib in the Treatment of Chronic Myeloid Leukaemia","volume":"45","author":"Lee","year":"2020","journal-title":"J Clin Pharm Ther"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0000000000000825","article-title":"Simultaneous Quantification of BCR-ABL and Bruton Tyrosine Kinase Inhibitors in Dried Plasma Spots and its Application to Clinical Sample Analysis","volume":"43","author":"Mukai","year":"2021","journal-title":"Ther Drug Monit"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.4155\/bio.14.171","article-title":"Quantifying Vemurafenib in Dried Blood Spots Using High-Performance LC-MS\/MS","volume":"6","author":"Nijenhuis","year":"2014","journal-title":"Bioanalysis"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.4155\/bio.15.235","article-title":"Development and Clinical Validation of an LC-MS\/MS Method for the Quantification of Pazopanib in DBS","volume":"8","author":"Verheijen","year":"2016","journal-title":"Bioanalysis"},{"key":"B46","doi-asserted-by":"publisher","first-page":"114623","DOI":"10.1016\/j.jpba.2022.114623","article-title":"Volumetric Absorptive Microsampling (VAMS) for the Quantification of Ten Kinase Inhibitors and Determination of Their In Vitro VAMS-To-Plasma Ratio","volume":"211","author":"Zimmermann","year":"2022","journal-title":"J Pharm BioMed Anal"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.4155\/bio.13.156","article-title":"Hemato-Critical Issues in Quantitative Analysis of Dried Blood Spots: Challenges and Solutions","volume":"5","author":"De Kesel","year":"2013","journal-title":"Bioanalysis"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2018.10.010","article-title":"Is the Hematocrit Still an Issue in Quantitative Dried Blood Spot Analysis","volume":"163","author":"Velghe","year":"2019","journal-title":"J Pharm BioMed Anal"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.4155\/bio-2021-0119","article-title":"Solutions for Hematocrit Bias in Dried Blood Spot Hormone Analysis","author":"de Kleijne","year":"2021","journal-title":"Bioanalysis"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0000000000000643","article-title":"Official International Association for Therapeutic Drug Monitoring and Clinical Toxicology Guideline: Development and Validation of Dried Blood Spot-Based Methods for Therapeutic Drug Monitoring","volume":"41","author":"Capiau","year":"2019","journal-title":"Ther Drug Monit"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2016.06.037","article-title":"Recent Developments in the Chromatographic Bioanalysis of Approved Kinase Inhibitor Drugs in Oncology","volume":"130","author":"Rood","year":"2016","journal-title":"J Pharm BioMed Anal"},{"key":"B52","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.chroma.2019.06.022","article-title":"Fully Automated Therapeutic Drug Monitoring of Anti-Epileptic Drugs Making Use of Dried Blood Spots","volume":"1601","author":"Velghe","year":"2019","journal-title":"J Chromatogr A"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.chroma.2021.462430","article-title":"Fully Automated Dried Blood Spot Extraction Coupled to Liquid Chromatography-Tandem Mass Spectrometry for Therapeutic Drug Monitoring of Immunosuppressants","volume":"1653","author":"Deprez","year":"2021","journal-title":"J Chromatogr A"},{"key":"B54","unstructured":"Immunosuppressant Microsampling2021"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1007\/s00216-018-0866-4","article-title":"Volumetric Absorptive Microsampling as an Alternative Tool for Therapeutic Drug Monitoring of First-Generation Anti-Epileptic Drugs","volume":"410","author":"Velghe","year":"2018","journal-title":"Anal Bioanal Chem"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1007\/s00216-018-1427-6","article-title":"Volumetric Absorptive Microsampling as an Alternative Sampling Strategy for the Determination of Paracetamol in Blood and Cerebrospinal Fluid","volume":"411","author":"Delahaye","year":"2019","journal-title":"Anal Bioanal Chem"},{"key":"B57","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.jpba.2018.04.001","article-title":"Extractability-Mediated Stability Bias and Hematocrit Impact: High Extraction Recovery is Critical to Feasibility of Volumetric Adsorptive Microsampling (VAMS) in Regulated Bioanalysis","volume":"156","author":"Xie","year":"2018","journal-title":"J Pharm BioMed Anal"},{"key":"B58","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1002\/dta.1646","article-title":"Dried Blood Spots: Concepts, Present Status, and Future Perspectives in Bioanalysis","volume":"6","author":"Sharma","year":"2014","journal-title":"Drug Test Anal"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1021\/ac303014b","article-title":"Prediction of the Hematocrit of Dried Blood Spots via Potassium Measurement on a Routine Clinical Chemistry Analyzer","volume":"85","author":"Capiau","year":"2013","journal-title":"Anal Chem"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1021\/acs.analchem.6b01321","article-title":"A Novel, Nondestructive, Dried Blood Spot-Based Hematocrit Prediction Method Using Noncontact Diffuse Reflectance Spectroscopy","volume":"88","author":"Capiau","year":"2016","journal-title":"Anal Chem"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1021\/acs.analchem.7b03784","article-title":"Correction for the Hematocrit Bias in Dried Blood Spot Analysis Using a Nondestructive, Single-Wavelength Reflectance-Based Hematocrit Prediction Method","volume":"90","author":"Capiau","year":"2018","journal-title":"Anal Chem"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2016.263053","article-title":"Measurement of Hematocrit in Dried Blood Spots Using Near-Infrared Spectroscopy: Robust, Fast, and Nondestructive","volume":"62","author":"Oostendorp","year":"2016","journal-title":"Clin Chem"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0000000000000834","article-title":"Development and Validation of Hematocrit Level Measurement in Dried Blood Spots Using Near-Infrared Spectroscopy","volume":"43","author":"van de Velde","year":"2021","journal-title":"Ther Drug Monit"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2021.10.002","article-title":"Near-Infrared-Based Hematocrit Prediction of Dried Blood Spots: An in-Depth Evaluation","volume":"523","author":"Delahaye","year":"2021","journal-title":"Clin Chim Acta"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1007\/s00216-014-8114-z","article-title":"Potassium-Based Algorithm Allows Correction for the Hematocrit Bias in Quantitative Analysis of Caffeine and its Major Metabolite in Dried Blood Spots","volume":"406","author":"De Kesel","year":"2014","journal-title":"Anal Bioanal Chem"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0000000000000864","article-title":"Alternative Sampling Devices to Collect Dried Blood Microsamples: State-of-the-Art","volume":"43","author":"Delahaye","year":"2021","journal-title":"Ther Drug Monit"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1021\/ac5022562","article-title":"Volumetric Absorptive Microsampling: A Dried Sample Collection Technique for Quantitative Bioanalysis","volume":"86","author":"Denniff","year":"2014","journal-title":"Anal Chem"},{"key":"B68","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.aca.2015.04.056","article-title":"Does Volumetric Absorptive Microsampling Eliminate the Hematocrit Bias for Caffeine and Paraxanthine in Dried Blood Samples? A Comparative Study","volume":"881","author":"De Kesel","year":"2015","journal-title":"Anal Chim Acta"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1515\/cclm-2016-0411","article-title":"Volumetric Absorptive Microsampling at Home as an Alternative Tool for the Monitoring of HbA1c in Diabetes Patients","volume":"55","author":"Verougstraete","year":"2017","journal-title":"Clin Chem Lab Med"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1515\/cclm-2018-0207","article-title":"Wet Absorptive Microsampling at Home for HbA1c Monitoring in Diabetic Children","volume":"56","author":"Verougstraete","year":"2018","journal-title":"Clin Chem Lab Med"},{"key":"B71","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.clinms.2017.08.004","article-title":"Application of Volumetric Absorptive Microsampling for Robust, High-Throughput Mass Spectrometric Quantification of Circulating Protein Biomarkers","author":"van den Broek","year":"2017","journal-title":"Clin Mass Spectrom"},{"key":"B72","volume-title":"Implementation of Tecan\u00ae Automation With Neoteryx Mitra\u00ae Volumetric Absorptive Microsampling for Reagent Preparation for an Anti-Drug Antibody Assay [Conference Poster Presentation]. SLAS 2019","author":"Yeung","year":"2019"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.4155\/bio.13.170","article-title":"The Effect of Hematocrit on Bioanalysis of DBS: Results From the EBF DBS-Microsampling Consortium","volume":"5","author":"de Vries","year":"2013","journal-title":"Bioanalysis"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.4155\/bio-2015-0028","article-title":"Evaluation of Sample Extraction Methods for Minimizing Hematocrit Effect on Whole Blood Analysis With Volumetric Absorptive Microsampling","volume":"9","author":"Ye","year":"2017","journal-title":"Bioanalysis"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2017.07.029","article-title":"Volumetric Absorptive Microsampling: Current Advances and Applications","volume":"147","author":"Kok","year":"2018","journal-title":"J Pharm BioMed Anal"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.4155\/bio-2017-0221","article-title":"Drug Monitoring by Volumetric Absorptive Microsampling: Method Development Considerations to Mitigate Hematocrit Effects","volume":"10","author":"Fang","year":"2018","journal-title":"Bioanalysis"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.4155\/bio.15.111","article-title":"Hematocrit-Independent Recovery is a Key for Bioanalysis Using Volumetric Absorptive Microsampling Devices, Mitra\u2122","volume":"7","author":"Mano","year":"2015","journal-title":"Bioanalysis"},{"key":"B78","doi-asserted-by":"publisher","first-page":"4996","DOI":"10.1021\/acs.analchem.5b00908","article-title":"Investigation of Different Approaches to Incorporating Internal Standards in DBS Quantitative Bioanalytical Workflows and Their Effect on Nullifying Hematocrit-Based Assay Bias","volume":"87","author":"Abu-Rabie","year":"2015","journal-title":"Anal Chem"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.4155\/bio.10.159","article-title":"Pharmacokinetic Considerations as to When to Use Dried Blood Spot Sampling","volume":"2","author":"Emmons","year":"2010","journal-title":"Bioanalysis"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-021-03036-6","article-title":"Dried Blood Spot Technique Applied in Therapeutic Drug Monitoring of Anticancer Drugs: A Review on Conversion Methods to Correlate Plasma and Dried Blood Spot Concentrations","volume":"38","author":"Iacuzzi","year":"2021","journal-title":"Pharm Res"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1021\/ac402735y","article-title":"Simple, Miniaturized Blood Plasma Extraction Method","volume":"85","author":"Kim","year":"2013","journal-title":"Anal Chem"},{"key":"B82","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.4155\/bio.15.98","article-title":"Novel Membrane Devices and Their Potential Utility in Blood Sample Collection Prior to Analysis of Dried Plasma Spots","volume":"7","author":"Sturm","year":"2015","journal-title":"Bioanalysis"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-019-02640-1","article-title":"Feasibility of and Patients\u2019 Perspective on Nilotinib Dried Blood Spot Self-Sampling","volume":"75","author":"Boons","year":"2019","journal-title":"Eur J Clin Pharmacol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1515\/cclm-2020-1180","article-title":"Self-Sampling at Home Using Volumetric Absorptive Microsampling: Coupling Analytical Evaluation to Volunteers\u2019 Perception in the Context of a Large Scale Study","volume":"59","author":"Van Uytfanghe","year":"2020","journal-title":"Clin Chem Lab Med"},{"key":"B85","doi-asserted-by":"crossref","DOI":"10.1002\/9781119615583.ch5","article-title":"\u201cAutomation in Microsampling: At Your Fingertips?\u201d","volume-title":"Patient Centric Blood Sampling and Quantitative Bioanalyis","author":"Deprez","year":""}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.821807\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,19]],"date-time":"2023-11-19T09:40:02Z","timestamp":1700386802000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.821807\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,22]]},"references-count":85,"alternative-id":["10.3389\/fonc.2022.821807"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.821807","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,22]]},"article-number":"821807"}}